{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T19:14:51Z","timestamp":1691522091073},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,2,20]],"date-time":"2009-02-20T00:00:00Z","timestamp":1235088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s00280-009-0939-3","type":"journal-article","created":{"date-parts":[[2009,2,19]],"date-time":"2009-02-19T08:41:10Z","timestamp":1235032870000},"page":"901-905","source":"Crossref","is-referenced-by-count":6,"title":["Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients"],"prefix":"10.1007","volume":"64","author":[{"given":"Jens","family":"Atzpodien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Morawek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fluck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Reitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,20]]},"reference":[{"issue":"4","key":"939_CR1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00008390-200508000-00010","volume":"15","author":"MS Vuoristo","year":"2005","unstructured":"Vuoristo MS, Hahka-Kemppinen M, Parvinen LM, Pyrh\u00f6nen S, Sepp\u00e4 H, Korpela M, Kellokumpu-Lehtinen P (2005) Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res 15(4):291\u2013296","journal-title":"Melanoma Res"},{"issue":"12","key":"939_CR2","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1517\/14656566.4.12.2205","volume":"4","author":"MB Lens","year":"2003","unstructured":"Lens MB, Eisen TG (2003) Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 4(12):2205\u20132211","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"939_CR3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.bjc.6600043","volume":"86","author":"J Atzpodien","year":"2002","unstructured":"Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Brocker EB, Neumann C, Runger TM, Schuler G, von den Driesch P, Muller I, Paul E, Patzelt T, Reitz M (2002) Combination chemotherapy with or without s.c. IL2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 86(2):179\u2013184","journal-title":"Br J Cancer"},{"issue":"5","key":"939_CR4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00000421-200210000-00007","volume":"25","author":"ME Stein","year":"2002","unstructured":"Stein ME, Bernstein Z, Tsalic M, Drumea K, Steiner M, Sklar Z, Haim N (2002) Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study. Am J Clin Oncol 25(5):460\u2013463","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"939_CR5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/bjc.1997.374","volume":"76","author":"CJ Punt","year":"1997","unstructured":"Punt CJ, van Herpen CM, Jansen RL, Vreugdenhil G, Muller EW, de Mulder PH (1997) Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. Br J Cancer 76(2):266\u2013269","journal-title":"Br J Cancer"},{"issue":"1","key":"939_CR6","first-page":"21","volume":"19","author":"L Serrone","year":"2000","unstructured":"Serrone L, Zeuli M, Sega FM, Cognetti F (2000) Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 19(1):21\u201334","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"939_CR7","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1158\/1535-7163.MCT-06-0402","volume":"6","author":"AG Polischouk","year":"2007","unstructured":"Polischouk AG, Holgersson A, Zong D, Stenerl\u00f6w B, Karlsson HL, M\u00f6ller L, Viktorsson K, Lewensohn R (2007) The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA double-strand break induced cell death. Mol Cancer Ther 6(8):2303\u20132309","journal-title":"Mol Cancer Ther"},{"key":"939_CR8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF01208613","volume":"118","author":"A Photiou","year":"1992","unstructured":"Photiou A, Sheik MN, bafaloukos D, Retsas S (1992) Antiproliferative activity of vinrelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol 118:249\u2013254","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"939_CR9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0959-8049(97)89023-5","volume":"33","author":"A Photiou","year":"1997","unstructured":"Photiou A, Shah P, Leong LK, Moss J, Retsas S (1997) In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer 33(3):463\u2013470","journal-title":"Eur J Cancer"},{"issue":"5 Suppl 10","key":"939_CR10","first-page":"14","volume":"21","author":"HA Burris III","year":"1994","unstructured":"Burris HAIII, Fields S (1994) Summary of data from in vitro and phase I vinorelbine (navelbine) studies. Semin Oncol 21(5 Suppl 10):14\u201319","journal-title":"Semin Oncol"},{"issue":"8","key":"939_CR11","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/cncr.20183","volume":"100","author":"RP Whitehead","year":"2004","unstructured":"Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, Tchekmedyian NS, Sondak VK, Southwest Oncology Group (2004) A phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer 100(8):1699\u20131704","journal-title":"Cancer"},{"issue":"3","key":"939_CR12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<584::AID-CNCR14>3.0.CO;2-#","volume":"88","author":"LG Feun","year":"2000","unstructured":"Feun LG, Savaraj N, Hurley J, Marini A, Lai S (2000) A clinical trial of intravenous vinrorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. Cancer 88(3):584\u2013588","journal-title":"Cancer"},{"issue":"6","key":"939_CR13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1081\/CNV-200039630","volume":"22","author":"H Gogas","year":"2004","unstructured":"Gogas H, Bafaloukos D, Aravantinos G, Fountzilas G, Tsoutsos D, Panagiotou P, Frangia K, Kalofonos HP, Briasoulis E, Castana O, Polyzos A, Pectasides D, Ioannovich J, Hellenic Cooperative Oncology Group (2004) Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Cancer Invest 22(6):832\u2013839","journal-title":"Cancer Invest"},{"issue":"4 Suppl 2","key":"939_CR14","first-page":"19","volume":"19","author":"JP Fruehauf","year":"2005","unstructured":"Fruehauf JP, Kong KM, Jakowatz JG (2005) Docetaxel and vinorelbine plus GM-CSF in malignant melanoma. Oncology 19(4 Suppl 2):19\u201322","journal-title":"Oncology"},{"issue":"6","key":"939_CR15","first-page":"572","volume":"27","author":"D Latz","year":"2004","unstructured":"Latz D, Nassar N, Frank R (2004) Trofosfamide in the palliative treatment of cancer: a review of the literature. Onkologie 27(6):572\u2013576","journal-title":"Onkologie"},{"issue":"2","key":"939_CR16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000227672","volume":"54","author":"E Salminen","year":"1997","unstructured":"Salminen E, Nikkanen V, Lindholm L (1997) Palliative chemotherapy in non-Hodgkin\u2019s lymphoma. Oncology 54(2):108\u2013111","journal-title":"Oncology"},{"issue":"10","key":"939_CR17","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/cncr.20574","volume":"101","author":"A Reichle","year":"2004","unstructured":"Reichle A, Bross K, Vogt T, Bataille F, Wild P, Berand A, Krause SW, Andreesen R (2004) Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 101(10):2247\u20132256","journal-title":"Cancer"},{"issue":"7","key":"939_CR18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s001050051158","volume":"51","author":"AH Enk","year":"2000","unstructured":"Enk AH, Knop J (2000) Stabilizing the course of patients with stage IV advanced malignant melanoma by trofosfamide treatment. Hautarzt 51(7):486\u2013489","journal-title":"Hautarzt"},{"issue":"9","key":"939_CR19","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","volume":"17","author":"PB Chapman","year":"1999","unstructured":"Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panagea KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9):2745\u20132751","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-0939-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-0939-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-0939-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:56Z","timestamp":1559038016000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-0939-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,20]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-0939-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,20]]}}}